<DOC>
	<DOCNO>NCT01074021</DOCNO>
	<brief_summary>Nimotuzumab IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical trial ongoing globally evaluate nimotuzumab different indication . Nimotuzumab grant approval use squamous cell carcinoma head neck ( SCCHN ) , glioma nasopharyngeal cancer different country . The Clinical efficacy show adult head neck cancer . The study assess clinical efficacy , safety combination Nimotuzumab administer concomitantly chemotherapy radiotherapy patient advanced nasopharyngeal cancer .</brief_summary>
	<brief_title>Nimotuzumab Combination With Chemoradiation Nasopharyngeal Cancer</brief_title>
	<detailed_description>Patients advanced nasopharyngeal cancer randomize 2 arm . The patient experimental arm treat Nimotuzumab use concurrently radiotherapy chemotherapy . The chemotherapy regimen Cisplatin monotherapy . The active comparator arm administer chemotherapy radiotherapy . The dose regimen experiment arm . The patients'hematopoietic , hepatic renal function test monitor weekly , physical exam reassessment tumor perform first fourth month , followup every six month evaluate survival index three year study .</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Joined study voluntary sign informed consent form Age 1870，both gender . Nasopharyngeal cancer confirm pathology . Nasopharyngeal cancer 2008 Stages : Ⅲ/Ⅳa . Primary lesion measurable . Karnofsky Performance Scale &gt; 70 . Life expectancy 6 month . Use effective contraceptive method woman risk pregnancy study . Haemoglobin≥100g/L , WBC ≥4×109/L , platelet count≥100×109/L Hepatic function : ALAT、ASAT &lt; 1.5 x ULN , TBIL &lt; 1.5 x ULN Renal function : Creatinine &lt; 1.5 x ULN Evidence distant metastasis Primary lesion lymph node operate ( except operation biopsy ) Previous radiotherapy Received anti EGFR monoclonal antibody treatment Previous chemotherapy immunization therapy Other malignant tumor ( except Nonmelanoma Skin Cancer carcinoma situ cervix ) Participation interventional clinical trial within 1 month Peripheral neuropathy I stage Pregnant breastfeeding woman woman refuse take contraceptive method History serious allergic allergy History Serious lung heart disease Refused ca n't sign informed consent form Drug abuse alcohol addiction Personality psychiatric disease , person without capacity civil conduct person limit capacity civil conduct</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Nimotuzumab</keyword>
	<keyword>Nasopharyngeal cancer</keyword>
	<keyword>chemoradiation</keyword>
</DOC>